Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.

Mandikian D, Takahashi N, Lo AA, Li J, Eastham-Anderson J, Slaga D, Ho J, Hristopoulos M, Clark R, Totpal K, Lin K, Joseph SB, Dennis MS, Prabhu S, Junttila TT, Boswell CA.

Mol Cancer Ther. 2018 Apr;17(4):776-785. doi: 10.1158/1535-7163.MCT-17-0657. Epub 2018 Jan 16.

2.

IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.

Li J, Ybarra R, Mak J, Herault A, De Almeida P, Arrazate A, Ziai J, Totpal K, Junttila MR, Walsh KB, Junttila TT.

Clin Cancer Res. 2018 Dec 15;24(24):6447-6458. doi: 10.1158/1078-0432.CCR-18-1139. Epub 2018 Jun 27.

PMID:
29950350
3.

An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.

Leong SR, Sukumaran S, Hristopoulos M, Totpal K, Stainton S, Lu E, Wong A, Tam L, Newman R, Vuillemenot BR, Ellerman D, Gu C, Mathieu M, Dennis MS, Nguyen A, Zheng B, Zhang C, Lee G, Chu YW, Prell RA, Lin K, Laing ST, Polson AG.

Blood. 2017 Feb 2;129(5):609-618. doi: 10.1182/blood-2016-08-735365. Epub 2016 Dec 1.

4.

Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties.

Ovacik AM, Li J, Lemper M, Danilenko D, Stagg N, Mathieu M, Ellerman D, Gupta V, Kalia N, Nguy T, Plaks V, David Johnson C, Wang W, Brumm J, Fine B, Junttila T, Lin K, Carter PJ, Prabhu S, Spiess C, Kamath AV.

MAbs. 2019 Feb/Mar;11(2):422-433. doi: 10.1080/19420862.2018.1551676. Epub 2018 Dec 17.

5.

Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3.

Slaga D, Ellerman D, Lombana TN, Vij R, Li J, Hristopoulos M, Clark R, Johnston J, Shelton A, Mai E, Gadkar K, Lo AA, Koerber JT, Totpal K, Prell R, Lee G, Spiess C, Junttila TT.

Sci Transl Med. 2018 Oct 17;10(463). pii: eaat5775. doi: 10.1126/scitranslmed.aat5775.

PMID:
30333240
6.

Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.

Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E, Mai E, Young J, Johnson C, Huseni M, Wang X, Chen Y, Wang P, Wang H, Dybdal N, Chu YW, Chiorazzi N, Scheer JM, Junttila T, Totpal K, Dennis MS, Ebens AJ.

Sci Transl Med. 2015 May 13;7(287):287ra70. doi: 10.1126/scitranslmed.aaa4802.

PMID:
25972002
7.

Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.

Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang BE, Li Y, Mathieu M, Li G, Young J, Luis E, Lewis Phillips G, Stefanich E, Spiess C, Polson A, Irving B, Scheer JM, Junttila MR, Dennis MS, Kelley R, Totpal K, Ebens A.

Cancer Res. 2014 Oct 1;74(19):5561-71. doi: 10.1158/0008-5472.CAN-13-3622-T. Epub 2014 Sep 16.

8.

Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice.

Shalaby MR, Carter P, Maneval D, Giltinan D, Kotts C.

Clin Immunol Immunopathol. 1995 Feb;74(2):185-92.

PMID:
7828373
9.

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.

Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, Eser M, McAleese F, Molkenthin V, Gall FL, Topp M, Little M, Zhukovsky EA.

MAbs. 2015;7(3):584-604. doi: 10.1080/19420862.2015.1029216.

10.

MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer.

Hernandez-Hoyos G, Sewell T, Bader R, Bannink J, Chenault RA, Daugherty M, Dasovich M, Fang H, Gottschalk R, Kumer J, Miller RE, Ravikumar P, Wiens J, Algate PA, Bienvenue D, McMahan CJ, Natarajan SK, Gross JA, Blankenship JW.

Mol Cancer Ther. 2016 Sep;15(9):2155-65. doi: 10.1158/1535-7163.MCT-15-0242. Epub 2016 Jul 12.

11.

Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.

Demanet C, Brissinck J, Leo O, Moser M, Thielemans K.

Cancer Res. 1994 Jun 1;54(11):2973-8.

12.

A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.

Bühler P, Wolf P, Gierschner D, Schaber I, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsässer-Beile U.

Cancer Immunol Immunother. 2008 Jan;57(1):43-52. Epub 2007 Jun 20.

13.
14.

Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.

Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsässer-Beile U.

Anticancer Res. 2000 May-Jun;20(3A):1551-5.

PMID:
10928069
15.

Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells.

Bortoletto N, Scotet E, Myamoto Y, D'Oro U, Lanzavecchia A.

Eur J Immunol. 2002 Nov;32(11):3102-7.

16.

A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.

Fisher TS, Hooper AT, Lucas J, Clark TH, Rohner AK, Peano B, Elliott MW, Tsaparikos K, Wang H, Golas J, Gavriil M, Haddish-Berhane N, Tchistiakova L, Gerber HP, Root AR, May C.

Cancer Immunol Immunother. 2018 Feb;67(2):247-259. doi: 10.1007/s00262-017-2081-0. Epub 2017 Oct 24.

PMID:
29067496
17.

Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.

Scheffold C, Kornacker M, Scheffold YC, Contag CH, Negrin RS.

Cancer Res. 2002 Oct 15;62(20):5785-91.

18.
19.

Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo.

Han H, Ma J, Zhang K, Li W, Liu C, Zhang Y, Zhang G, Ma P, Wang L, Zhang G, Tao H, Gao B.

Int J Oncol. 2014 Dec;45(6):2446-54. doi: 10.3892/ijo.2014.2663. Epub 2014 Sep 18.

PMID:
25242665
20.

Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.

Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG.

Clin Cancer Res. 2006 Jan 15;12(2):569-76.

Supplemental Content

Support Center